Novelrad

Novelrad is a medical technology company focused on developing minimally-invasive micro-suturing technology to enhance patient care and reduce treatment costs in cardiovascular procedures. Their core innovation is a micro-sewing machine that allows for the creation of multipoint continuous suture patterns percutaneously, mimicking traditional surgical techniques without the need for open surgery. This technology primarily addresses vascular and heart defect closures, particularly in large-bore vascular access sites. The company's flagship product, the Transcatheter Continuous Sutures Device (NVCD), enables the safe and reliable placement of purse-string sutures around vascular access sites. This device is designed for various cardiovascular applications, including intracardiac procedures like Patent Foramen Ovale (PFO) closure. Novelrad aims to improve patient outcomes by reducing procedure times, hospitalization lengths, and complication rates, while supporting healthcare providers in delivering high-quality care. The company has received recognition for its innovative approach, including a €2.5 million grant from the European Commission’s EIC Accelerator program.

• Employees 10
• Founded 2019